![ISPOR Europe 2024 – May 5-8. Register now.]({"type":"image" , "src" : "/sda/112342/JournalAd-ISPOR-2024-Leaderboard.jpg"})
References
- Chambers JD . Can the US Afford to Ignore Cost-Effectiveness Evidence in Health Care. Office of Health Economics Seminar Briefing 13. 2014 Available from https://www.ohe.org/publications/can-us-afford-ignore-cost-effectiveness-evidence [Last accessed on 27 Oct 2014]
- Washington State Health Care Authority. Health technology assessment program . Available from: www.hca.wa.gov/hta/Pages/index.aspx [Last accessed on 27 Oct 2014]
- Department of Defense. Department of Defense (DoD) Pharmacoeconomic Center (PEC) . Available from: http://pec.ha.osd.mil/ [Last accessed on 27 Oct 2014]
- Department of Veteran Affairs. Department of Veteran Affairs Health Economic Resource Center (HERC) . Available from: www.herc.research.va.gov/home/default.asp [Last accessed on 27 Oct 2014]
- Academy of Managed Care Pharmacy . The AMCP format for formulary submissions version 3.0. J Manag Care Pharm 2010;16(1 Suppl A):1-30
- WellPoint . Health Technology Assessment Guidelines. Drug Submission Guidelines for Re-Evaluation of Products, Indications, and Formulations. National Pharmacy and Therapeutics Committee. 2008. Available from: www.pharmamedtechbi.com/∼/media/Images/Publications/Archive/The%20Pink%20Sheet/70/043/00700430001/wellpoint_formulary_guidelines.pdf [Last accessed on 27 Oct 2014]
- Watkins J , Sullivan SD , Wong E , et al. Implementing a value-based formulary pilot in a U.S. Commercial Self-insured Group. International Society for Pharmacoeconomics and Outcomes Research; Baltimore, MD, USA; 2011
- Neumann PJ , Fang CH , Cohen JT . 30 years of pharmaceutical cost-utility analyses: growth, diversity and methodological improvement. Pharmacoeconomics 2009;27(10):861-72
- Tufts Medical Center Cost-Effectiveness Analysis (CEA) Registry . Available from: www.cearegistry.org [Last accessed on 27 Oct 2014]
- Thorat TJ , Cangelosi MJ , Neumann PJ . Skills of the trade: the tufts cost-effectiveness analysis (CEA) Registry. J Benefit-Cost Anal 2012;3(1):1-9
- Neumann PJ . What next for QALYs? JAMA 2011;305(17):1806-7
- Chambers JD . Do changes in drug coverage policy point to an increased role for cost-effectiveness analysis in the USA? Pharmacoeconomics 2014;32(8):729-33
- Anderson JL , Heidenreich PA , Barnett PG , et al. ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63(21):2304-22
- American Society of Clinical Oncology . Value in cancer care task force. Available from: www.asco.org/practice-research/value-cancer-care [Last accessed on 27 Oct 2014]
- Neumann PJ , Weinstein MC . Legislating against use of cost-effectiveness information. N Engl J Med 2010;363(16):1495-7
- Botta MD , Blendon RJ , Benson JM . Cost-effectiveness decision making and US public opinion. JAMA Intern Med 2014;174(1):141-3